Verona Pharma plc — Director's Dealing 2025

Feb 28, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2025-02-26

Reporting Person: EBSWORTH DAVID R (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-26	Ordinary Shares	M	64000	$0.775	Acquired	1004003	Direct
2025-02-26	Ordinary Shares	M	200000	$0.5038	Acquired	1204003	Direct
2025-02-26	Ordinary Shares	M	96000	$2.67	Acquired	1300003	Direct
2025-02-26	Ordinary Shares	M	100000	$1.9338	Acquired	1400003	Direct
2025-02-26	Ordinary Shares	G	64000	—	Disposed	1336003	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-26	Share Option (Right to Exercise)	$0.775	M	64000	Disposed	2031-08-08	Ordinary Shares (64000)	Direct
2025-02-26	Share Option (Right to Exercise)	$0.5038	M	200000	Disposed	2032-04-27	Ordinary Shares (200000)	Direct
2025-02-26	Share Option (Right to Exercise)	$2.67	M	96000	Disposed	2033-04-27	Ordinary Shares (96000)	Direct
2025-02-26	Share Option (Right to Exercise)	$1.9338	M	100000	Disposed	2034-04-28	Ordinary Shares (100000)	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Consists of (i) 1,336,000 Ordinary Shares represented by 167,000 ADSs and (ii) 3 Ordinary Shares.

F3: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4: The option is fully vested.

F5: The option vests and becomes exercisable as to 25% on each of July 29, 2024, October 29, 2024, January 29, 2025 and April 29, 2025.